NCT07222384
A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That Are Considered at Higher Risk of Severe COVID-19
Registry fields
- Overall status
- COMPLETED
- Conditions
- COVID-19, SARS-COV-2 Infection
- Study type
- INTERVENTIONAL
- Phase
- PHASE3
- Primary purpose
- PREVENTION
- Intervention type
- BIOLOGICAL
- Interventions
- BNT162b2 (2025/2026 formulation)
- Lead sponsor
- BioNTech SE (INDUSTRY)
Cached at: 2026-08-09 12:53:31
Brief summary
The purpose of this study is to learn about the safety, tolerability, and immunogenicity of an updated vaccine against COVID-19, called BNT162b2 (2025/2026 formulation).
This study is seeking participants 5 through 11 years of age who:
* have at least 1 underlying condition that puts them at high risk for severe outcomes from COVID-19,
* and are medically stable.
All participants in this study will receive 1 vaccine dose given in the muscle of their arm of a BNT162b2 (2025/2026 formulation) vaccine which targets the COVID-19 virus, specifically the strain selected for the 2025-2026 COVID-19 viral respiratory season.
Participants will take part in this study for about 6 months and will need to visit the clinical study site at least 2 times.
This study is seeking participants 5 through 11 years of age who:
* have at least 1 underlying condition that puts them at high risk for severe outcomes from COVID-19,
* and are medically stable.
All participants in this study will receive 1 vaccine dose given in the muscle of their arm of a BNT162b2 (2025/2026 formulation) vaccine which targets the COVID-19 virus, specifically the strain selected for the 2025-2026 COVID-19 viral respiratory season.
Participants will take part in this study for about 6 months and will need to visit the clinical study site at least 2 times.
Contact
Need a report or Korean medical writing based on this trial?
Sign in with Kakao to continue